Abstract
Context: The COVID-19 pandemic rapidly spread from China to other countries. The clinical features of patients with COVID-19 have revealed a few potential biochemical markers associated with in-hospital mortality. Numerous studies have proposed the use of hematological markers that seem to be associated with increased severity and mortality in patients with COVID-19. Objective: To evaluate the prognostic value of some hematological parameters and the effect of inflammatory biomarkers on overall survival (OS) and mortality of patients with hematological malignancies infected with COVID-19. Design: A cross-sectional study. Setting: Clinical Hematology Department, Ain Shams University Hospital, over the period of December 2020 to October 2021. Patients or Other Participants: Fifty adult Egyptian patients with different hematological malignancies. Interventions: All participants gave a full history and underwent thorough physical examination and laboratory measures that included hematological and immune parameters and some coagulation tests. All laboratory parameters were measured using Sysmex XN-1000 (hematological parameter), Beckman Coulter Chemistry Analyzer AU 480, and Stago Max. Main Outcome Measures: We found significant correlations between biochemical markers and OS. Results: The median neutrophil-to-monocyte ratio (NMR) was 7.40 (IQR: 3.0–16.67, range: 0–110)× 10(3)/µL, and there is significant correlation between NMR and OS (P=0.031). There is significant correlation between OS of these patients and D-dimer, ferritin, hematocrit (HCT), and red blood cell (RBC) count. Conclusions: There are simple, easy, and rapid tests, such as the NMR, inflammatory biomarkers (ferritin and D-dimer), and some hematological parameters (HCT, RBC), that have prognostic value for OS and mortality for patients with hematological malignancies infected with COVID-19.